Hosted on MSN

FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911

The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular ...
Morningstar%2c Inc.

New Drug Application for "K-911" Targeting Patients with Glaucoma and Ocular Hypertension Accepted for Filing in the U.S., Food and Drug Administration

NAGOYA, Japan, Aug. 27, 2026 /PRNewswire/ -- Kowa Company, Ltd. (hereafter referred to as "Kowa") is developing K-911 for the indication of reducing intraocular pressure (IOP) in patients with ...
Yahoo Finance

Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or ...

MONTGOMERY, Ala., Aug. 27, 2026 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. (KPA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug ...
Monthly Prescribing Reference

FDA Accepts NDA for K-911 to Reduce Intraocular Pressure in Glaucoma

A Prescription Drug User Fee Act target date of April 30, 2027 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for K-911 ...
Morningstar%2c Inc.

Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or ...

FDA assigns PDUFA target action date of April 30, 2027 MONTGOMERY, Ala., Aug. 27, 2026 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. (KPA), today announced that the U.S. Food and Drug ...